First-of-its-Kind trial aims to stop cancer growth in patients who have run out of options
NCT ID NCT03091257
Summary
This is an early-stage study testing whether two targeted cancer drugs, dabrafenib and trametinib, can help control multiple myeloma that has returned or stopped responding to other treatments. The trial is for up to 30 adults whose cancer cells have specific genetic changes (BRAF, KRAS, or NRAS mutations). Researchers want to see if blocking these mutated proteins can safely slow or stop the cancer's growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.